Acquisition history Amplion was acquired by Science & Medicine Group in September 2022, indicating past consolidation in life sciences data intelligence and suggesting potential overlap or integration opportunities for customers using Amplion's legacy platforms.

Revenue constraints Current revenue is under one million with total funding of 2.6 million, signaling a small, early-stage operation that could benefit from larger pharma partnerships, channel collaborations, or co-marketing arrangements to scale lead generation for life science products.

Target customer fit Offering focuses on life science marketing and sales teams seeking rapid, ML-driven opportunity insights, implying ideal B2B customers are biotech firms, CROs, pharma partnerships, and research institutions needing high-velocity lead lists.

Product evolution Dx:Revenue lineage across multiple launches (2019 and 2022) shows continued product development in software intelligence for partnerships, suggesting upsell or cross-sell opportunities to firms already aware of the platform’s capabilities.

Competitive positioning With a niche in precision medicine intelligence and AI-powered data insights, Amplion sits in a market with larger data players; identify partners or customers seeking specialized life-science event alerts and curated opportunities to differentiate from broad market tools.